Cargando…

Characterization of Ebola Virus–Associated Eye Disease

IMPORTANCE: Survivors of Ebola virus disease (EVD) may experience ocular sequelae. Comparison with antibody-negative individuals from the local population is required to characterize the disease. OBJECTIVE: To assess features of ophthalmic disease specific to EVD. DESIGN, SETTING, AND PARTICIPANTS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Eghrari, Allen O., Bishop, Rachel J., Ross, Robin D., Davis, Bionca, Larbelee, Jemma, Amegashie, Fred, Dolo, Robert F., Prakalapakorn, S. Grace, Gaisie, Catherine, Gargu, Catherine, Sosu, Yassah, Sackor, Jennie, Cooper, Precious Z., Wallace, Augustine, Nyain, Ruth, Gray, Maima, Kamara, Famatta, Burkholder, Bryn, Brady, Christopher J., Ray, Vincent, Tawse, Kirstin L., Yeung, Ian, Neaton, James D., Higgs, Elizabeth S., Lane, H. Clifford, Reilly, Cavan, Sneller, Michael C., Fallah, Mosoka P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786253/
https://www.ncbi.nlm.nih.gov/pubmed/33399856
http://dx.doi.org/10.1001/jamanetworkopen.2020.32216
_version_ 1783632588222496768
author Eghrari, Allen O.
Bishop, Rachel J.
Ross, Robin D.
Davis, Bionca
Larbelee, Jemma
Amegashie, Fred
Dolo, Robert F.
Prakalapakorn, S. Grace
Gaisie, Catherine
Gargu, Catherine
Sosu, Yassah
Sackor, Jennie
Cooper, Precious Z.
Wallace, Augustine
Nyain, Ruth
Gray, Maima
Kamara, Famatta
Burkholder, Bryn
Brady, Christopher J.
Ray, Vincent
Tawse, Kirstin L.
Yeung, Ian
Neaton, James D.
Higgs, Elizabeth S.
Lane, H. Clifford
Reilly, Cavan
Sneller, Michael C.
Fallah, Mosoka P.
author_facet Eghrari, Allen O.
Bishop, Rachel J.
Ross, Robin D.
Davis, Bionca
Larbelee, Jemma
Amegashie, Fred
Dolo, Robert F.
Prakalapakorn, S. Grace
Gaisie, Catherine
Gargu, Catherine
Sosu, Yassah
Sackor, Jennie
Cooper, Precious Z.
Wallace, Augustine
Nyain, Ruth
Gray, Maima
Kamara, Famatta
Burkholder, Bryn
Brady, Christopher J.
Ray, Vincent
Tawse, Kirstin L.
Yeung, Ian
Neaton, James D.
Higgs, Elizabeth S.
Lane, H. Clifford
Reilly, Cavan
Sneller, Michael C.
Fallah, Mosoka P.
author_sort Eghrari, Allen O.
collection PubMed
description IMPORTANCE: Survivors of Ebola virus disease (EVD) may experience ocular sequelae. Comparison with antibody-negative individuals from the local population is required to characterize the disease. OBJECTIVE: To assess features of ophthalmic disease specific to EVD. DESIGN, SETTING, AND PARTICIPANTS: This baseline cross-sectional analysis of survivors of EVD and their close contacts was conducted within PREVAIL III, a 5-year, longitudinal cohort study. Participants who enrolled at John F. Kennedy Medical Center in Liberia, West Africa from June 2015 to March 2016 were included in this analysis. Close contacts were defined as household members or sex partners of survivors of EVD. Data were analyzed from July 2016 to July 2020. EXPOSURES: All participants, both survivors and close contacts, underwent testing of IgG antibody levels against Ebola virus surface glycoprotein. MAIN OUTCOMES AND MEASURES: Ocular symptoms, anterior and posterior ophthalmologic examination findings, and optical coherence tomography images were compared between antibody-positive survivors and antibody-negative close contacts. RESULTS: A total of 564 antibody-positive survivors (320 [56.7%] female; mean [SD] age, 30.3 [14.0] years) and 635 antibody-negative close contacts (347 [54.6%] female; mean [SD] age, 25.8 [15.5] years) were enrolled in this study. Survivors were more likely to demonstrate color vision deficit (28.9% vs 19.0%, odds ratio [OR], 1.6; 95% CI, 1.2-2.1) and lower intraocular pressure (12.4 vs 13.5 mm Hg; mean difference, −1.2 mm Hg; 95% CI, −1.6 to −0.8 mm Hg) compared with close contacts. Dilated fundus examination revealed a higher percentage of vitreous cells (7.8% vs 0.5%; OR, 16.6; 95% CI, 5.0-55.2) and macular scars (4.6% vs 1.6%; OR, 2.8; 95% CI, 1.4-5.5) in survivors than in close contacts. Uveitis was present in 26.4% of survivors and 12.1% of close contacts (OR, 2.4; 95% CI, 1.8-3.2). Among all participants with uveitis, survivors were more likely than close contacts to have intermediate uveitis (34.2% vs 6.5% of all cases; OR, 7.8; 95% CI, 3.1-19.7) and had thicker mean central subfield thickness on optical coherence tomography (222 vs 212 μm; mean difference, 14.4 μm; 95% CI, 1.9-26.9 μm). CONCLUSIONS AND RELEVANCE: In this cross-sectional study, survivors of EVD had a distinct spectrum of ocular and neuro-ophthalmologic findings compared with close contacts that potentially require medical and surgical treatment.
format Online
Article
Text
id pubmed-7786253
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-77862532021-01-15 Characterization of Ebola Virus–Associated Eye Disease Eghrari, Allen O. Bishop, Rachel J. Ross, Robin D. Davis, Bionca Larbelee, Jemma Amegashie, Fred Dolo, Robert F. Prakalapakorn, S. Grace Gaisie, Catherine Gargu, Catherine Sosu, Yassah Sackor, Jennie Cooper, Precious Z. Wallace, Augustine Nyain, Ruth Gray, Maima Kamara, Famatta Burkholder, Bryn Brady, Christopher J. Ray, Vincent Tawse, Kirstin L. Yeung, Ian Neaton, James D. Higgs, Elizabeth S. Lane, H. Clifford Reilly, Cavan Sneller, Michael C. Fallah, Mosoka P. JAMA Netw Open Original Investigation IMPORTANCE: Survivors of Ebola virus disease (EVD) may experience ocular sequelae. Comparison with antibody-negative individuals from the local population is required to characterize the disease. OBJECTIVE: To assess features of ophthalmic disease specific to EVD. DESIGN, SETTING, AND PARTICIPANTS: This baseline cross-sectional analysis of survivors of EVD and their close contacts was conducted within PREVAIL III, a 5-year, longitudinal cohort study. Participants who enrolled at John F. Kennedy Medical Center in Liberia, West Africa from June 2015 to March 2016 were included in this analysis. Close contacts were defined as household members or sex partners of survivors of EVD. Data were analyzed from July 2016 to July 2020. EXPOSURES: All participants, both survivors and close contacts, underwent testing of IgG antibody levels against Ebola virus surface glycoprotein. MAIN OUTCOMES AND MEASURES: Ocular symptoms, anterior and posterior ophthalmologic examination findings, and optical coherence tomography images were compared between antibody-positive survivors and antibody-negative close contacts. RESULTS: A total of 564 antibody-positive survivors (320 [56.7%] female; mean [SD] age, 30.3 [14.0] years) and 635 antibody-negative close contacts (347 [54.6%] female; mean [SD] age, 25.8 [15.5] years) were enrolled in this study. Survivors were more likely to demonstrate color vision deficit (28.9% vs 19.0%, odds ratio [OR], 1.6; 95% CI, 1.2-2.1) and lower intraocular pressure (12.4 vs 13.5 mm Hg; mean difference, −1.2 mm Hg; 95% CI, −1.6 to −0.8 mm Hg) compared with close contacts. Dilated fundus examination revealed a higher percentage of vitreous cells (7.8% vs 0.5%; OR, 16.6; 95% CI, 5.0-55.2) and macular scars (4.6% vs 1.6%; OR, 2.8; 95% CI, 1.4-5.5) in survivors than in close contacts. Uveitis was present in 26.4% of survivors and 12.1% of close contacts (OR, 2.4; 95% CI, 1.8-3.2). Among all participants with uveitis, survivors were more likely than close contacts to have intermediate uveitis (34.2% vs 6.5% of all cases; OR, 7.8; 95% CI, 3.1-19.7) and had thicker mean central subfield thickness on optical coherence tomography (222 vs 212 μm; mean difference, 14.4 μm; 95% CI, 1.9-26.9 μm). CONCLUSIONS AND RELEVANCE: In this cross-sectional study, survivors of EVD had a distinct spectrum of ocular and neuro-ophthalmologic findings compared with close contacts that potentially require medical and surgical treatment. American Medical Association 2021-01-05 /pmc/articles/PMC7786253/ /pubmed/33399856 http://dx.doi.org/10.1001/jamanetworkopen.2020.32216 Text en Copyright 2021 Eghrari AO et al. JAMA Network Open. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Eghrari, Allen O.
Bishop, Rachel J.
Ross, Robin D.
Davis, Bionca
Larbelee, Jemma
Amegashie, Fred
Dolo, Robert F.
Prakalapakorn, S. Grace
Gaisie, Catherine
Gargu, Catherine
Sosu, Yassah
Sackor, Jennie
Cooper, Precious Z.
Wallace, Augustine
Nyain, Ruth
Gray, Maima
Kamara, Famatta
Burkholder, Bryn
Brady, Christopher J.
Ray, Vincent
Tawse, Kirstin L.
Yeung, Ian
Neaton, James D.
Higgs, Elizabeth S.
Lane, H. Clifford
Reilly, Cavan
Sneller, Michael C.
Fallah, Mosoka P.
Characterization of Ebola Virus–Associated Eye Disease
title Characterization of Ebola Virus–Associated Eye Disease
title_full Characterization of Ebola Virus–Associated Eye Disease
title_fullStr Characterization of Ebola Virus–Associated Eye Disease
title_full_unstemmed Characterization of Ebola Virus–Associated Eye Disease
title_short Characterization of Ebola Virus–Associated Eye Disease
title_sort characterization of ebola virus–associated eye disease
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786253/
https://www.ncbi.nlm.nih.gov/pubmed/33399856
http://dx.doi.org/10.1001/jamanetworkopen.2020.32216
work_keys_str_mv AT eghrarialleno characterizationofebolavirusassociatedeyedisease
AT bishoprachelj characterizationofebolavirusassociatedeyedisease
AT rossrobind characterizationofebolavirusassociatedeyedisease
AT davisbionca characterizationofebolavirusassociatedeyedisease
AT larbeleejemma characterizationofebolavirusassociatedeyedisease
AT amegashiefred characterizationofebolavirusassociatedeyedisease
AT dolorobertf characterizationofebolavirusassociatedeyedisease
AT prakalapakornsgrace characterizationofebolavirusassociatedeyedisease
AT gaisiecatherine characterizationofebolavirusassociatedeyedisease
AT gargucatherine characterizationofebolavirusassociatedeyedisease
AT sosuyassah characterizationofebolavirusassociatedeyedisease
AT sackorjennie characterizationofebolavirusassociatedeyedisease
AT cooperpreciousz characterizationofebolavirusassociatedeyedisease
AT wallaceaugustine characterizationofebolavirusassociatedeyedisease
AT nyainruth characterizationofebolavirusassociatedeyedisease
AT graymaima characterizationofebolavirusassociatedeyedisease
AT kamarafamatta characterizationofebolavirusassociatedeyedisease
AT burkholderbryn characterizationofebolavirusassociatedeyedisease
AT bradychristopherj characterizationofebolavirusassociatedeyedisease
AT rayvincent characterizationofebolavirusassociatedeyedisease
AT tawsekirstinl characterizationofebolavirusassociatedeyedisease
AT yeungian characterizationofebolavirusassociatedeyedisease
AT neatonjamesd characterizationofebolavirusassociatedeyedisease
AT higgselizabeths characterizationofebolavirusassociatedeyedisease
AT lanehclifford characterizationofebolavirusassociatedeyedisease
AT reillycavan characterizationofebolavirusassociatedeyedisease
AT snellermichaelc characterizationofebolavirusassociatedeyedisease
AT fallahmosokap characterizationofebolavirusassociatedeyedisease